Journal
SEMINARS IN THROMBOSIS AND HEMOSTASIS
Volume -, Issue -, Pages -Publisher
THIEME MEDICAL PUBL INC
DOI: 10.1055/s-0043-1775568
Keywords
cancer; thrombosis; blood group; antigens; von Willebrand factor
Categories
Ask authors/readers for more resources
Cancer-associated thrombosis, especially venous thromboembolism, is associated with ABO blood groups, with non-O blood type and increased VWF levels showing a strong correlation with increased VTE risk. However, there are varying results in different studies and more research is needed to understand the role of ABO blood groups and other risk factors in different cancer types.
Cancer-associated thrombosis (CT), especially venous thromboembolism (VTE), is a common occurrence with several factors contributing to a wide diversity in thrombosis risk. The association between ABO blood groups and the risk for CT has been examined in various studies, with non-O blood type associated with an increased thrombosis risk; however, these studies have reported varying results with recognized limitations. ABO blood groups are known to be implicated in hemostasis, in an association mediated through von Willebrand factor (VWF). In this narrative review, we aim to summarize the current knowledge surrounding the role of ABO blood groups in VTE, with a particular focus on the role of VWF and other contributing risk factors on VTE occurrence. We found evidence from literature for the impact of ABO blood groups in determining the risk of VTE in healthy populations, with a limited number of studies examining this effect in cancer patients. Additionally, research on the impact of ABO on different cancer types lacks rigor, particularly in regard to other risk factors. Overall, most studies showed strong association of increased risk of VTE amongst cancer patients with non-O blood groups and increased VWF levels. This association was weaker in a few studies. Further research is needed before a solid conclusion can be made about the ABO or ABO-VWF-mediated hypercoagulability and VTE risk in various cancers. These studies will help determine if ABO typing can be an added biomarker to improve VTE risk assessment models in cancer patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available